Page 150 - Genentech News Today

The company said it is seeking a buyer that will continue to use the plant as an operating facility.

Expert discusses the long wait for an effective therapeutic option for persistent, recurrent, or metastatic cervical cancer and the potential widespread benefits of antibody drug conjugates like pembrolizumab.

CHICAGO — One-year of adjuvant trastuzumab remains the standard-of-care treatment duration for most patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.However, certain patients with low/intermediate HER2-positive early breast cancer may benefit from a shorter, 9-week course of trastuzumab (Herceptin, Genentech), researchers noted.

CHICAGO — Adding talazoparib to atezolizumab as maintenance treatment after front-line chemoimmunotherapy significantly lengthened PFS among adults with SLFN11-positive extensive-stage small cell lung cancer, according to a phase 2 study.Results of the randomized trial presented at ASCO Annual Meeting suggested that a biomarker-based approach to treating small cell lung cancer is feasible

CHICAGO — Individuals with high-risk hepatocellular carcinoma undergoing curative-intent procedures did not experience clinically meaningful deterioration in quality of life or function after adjuvant therapy, phase 3 study results showed.Patient-reported outcomes from the randomized IMbrave050 trial presented at ASCO Annual Meeting suggest that an adjuvant regimen of atezolizumab plus

Beneath and beyond the reddish, flaky lesions that form in the skin of those with psoriasis, mild and severe forms of the disease can be told apart by the activity of key cells and signaling pathways, a new study shows.

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity.

The Human Cell Atlas is already helping to ensure safer pregnancies, and scientists believe it will help them understand many other conditions

Expert said that manufacturing the T cells with a tyrosine kinase inhibitor may allow more patients to get allogeneic stem cell transplant, the current best means of long-term cure.

CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab — followed by maintenance durvalumab, bevacizumab and olaparib — extended PFS compared with standard of care for women with non-BRCA-mutated advanced ovarian cancer.The findings of an interim analysis of the three-arm, randomized phase 3 DUO-O trial, presented at ASCO Annual Meeting, also noted a numerical